AR051940A1 - Compuestos y metodos para modular la actividad de la trombopoyetina - Google Patents
Compuestos y metodos para modular la actividad de la trombopoyetinaInfo
- Publication number
- AR051940A1 AR051940A1 ARP050104466A ARP050104466A AR051940A1 AR 051940 A1 AR051940 A1 AR 051940A1 AR P050104466 A ARP050104466 A AR P050104466A AR P050104466 A ARP050104466 A AR P050104466A AR 051940 A1 AR051940 A1 AR 051940A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- ring
- aliphatic
- hydrogen
- haloaliphatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Compuestos arilhidrazino sustituidos, composiciones farmacéuticas que los comprenden, métodos que los utilizan para modular la actividad de un receptor de trombopoyetina, métodos para identificar compuestos como moduladores del receptor de trombopoyetina, y métodos para tratar una enfermedad administrando un compuesto de la presente a un paciente que necesite dicho tratamiento. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), o una sal, un éster, una amida o una prodroga aceptables para uso farmacéutico del mismo, donde: R1 se selecciona entre CO2R10, CONR10R11, SO3R10, y un bioisostero de ácido carboxílico; R2 y R3 se seleccionan en forma independiente entre sí entre ausente, hidrogeno, OR12, NR12R13, alifático C1-4 opcionalmente sustituido, haloalifático C1-4, opcionalmente sustituido, heteroalifático C1-4 opcionalmente sustituido, anillo opcionalmente sustituido, y (CH2)mR14; o R2 y R3 tomados juntos forman una olefina opcionalmente sustituida; o R2 y R3 se unen para formar un anillo C3-6 opcionalmente sustituido; R4 se selecciona entre hidrogeno, F, Cl, Br, alifático C1-4, haloalifático C1-4, heteroalifático C1-4, y un anillo; R5 se selecciona entre hidrogeno, OR10, SR10, NHR11, y CO2H; R6 se selecciona entre hidrogeno, OR12, NR12R13, F, Cl, Br, alquilo C1-4, haloalquilo C1-4, heteroalquilo C1-4, y un anillo; R7 se selecciona entre hidrogeno, alifático C1-8 opcionalmente sustituido, haloalifático C1-8 opcionalmente sustituido, heteroalifático C1-6 opcionalmente sustituido, heterohaloalifático C1-8 opcionalmente sustituido, anillo opcionalmente sustituido, y (CH2)mR14; R10 se selecciona entre hidrogeno, alifático C1-4 opcionalmente sustituido, haloalifático C1- 4, heteroalifático C1-4, y un anillo; R11 se selecciona entre hidrogeno, SO2R15, alifático C1-4, haloalifático C1-4, heteroalifático C1-4, y un anillo; R112 y R13 se seleccionan en forma independiente entre sí entre hidrogeno, alifático C1-4 opcionalmente sustituido, haloalifático C1-4 opcionalmente sustituido, heteroalifático C1-4 opcionalmente sustituido, un anillo opcionalmente sustituido, y (CH2)mR14; o uno de R12 y R13 es alifático C2-6 opcionalmente sustituido o un anillo opcionalmente sustituido y el otro de R12 y R13 está ausente; o R12 y R13 se unen para formar un anillo C3-8 opcionalmente sustituido; R14 se selecciona entre un arilo opcionalmente sustituido y un heteroarilo opcionalmente sustituido; R15 se selecciona entre hidrogeno, alifático C1-3, haloalifático C1-3, y un anillo; Y es un separador de 1-4 átomos que comprende uno o más grupos seleccionados entre un alifático C1-6 opcionalmente sustituido, heteroalifático C1-6 opcionalmente sustituido, un fenilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido, heterociclo C3-5 opcionalmente sustituido, y un alicíclico opcionalmente sustituido; con la condicion de que Y no sea -N=CR6- orientado para formar un dihidropirazol; Z se selecciona entre: un separador de 2-5 átomos seleccionados entre un arilo C6-10 opcionalmente sustituido y heteroarilo C1-6 opcionalmente sustituido; y un separador de 1-5 átomos seleccionado entre alifático C1-6 opcionalmente sustituido, heteroalifático C1-6 opcionalmente sustituido, y haloalifático C1-6 opcionalmente sustituido; m es 0, 1, o 2; y n es 0 o 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62187904P | 2004-10-25 | 2004-10-25 | |
US67500105P | 2005-04-25 | 2005-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051940A1 true AR051940A1 (es) | 2007-02-21 |
Family
ID=35610075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104466A AR051940A1 (es) | 2004-10-25 | 2005-10-25 | Compuestos y metodos para modular la actividad de la trombopoyetina |
Country Status (15)
Country | Link |
---|---|
US (3) | US7314887B2 (es) |
EP (1) | EP1805155B1 (es) |
JP (1) | JP4728340B2 (es) |
KR (1) | KR100958337B1 (es) |
AR (1) | AR051940A1 (es) |
AT (1) | ATE486859T1 (es) |
AU (1) | AU2005299720B2 (es) |
BR (1) | BRPI0516883A (es) |
CA (1) | CA2583764C (es) |
DE (1) | DE602005024599D1 (es) |
IL (2) | IL182763A (es) |
MX (1) | MX2007004765A (es) |
NO (1) | NO20072199L (es) |
NZ (1) | NZ554662A (es) |
WO (1) | WO2006047344A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
KR100958337B1 (ko) * | 2004-10-25 | 2010-05-17 | 리간드 파마슈티칼스 인코포레이티드 | 트롬보포이에틴 활성 조절 화합물 및 방법 |
WO2007062078A2 (en) * | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
AU2007329464A1 (en) * | 2006-12-01 | 2008-06-12 | Stategics, Inc. | Thrombopoietin mimetics |
WO2008073864A1 (en) * | 2006-12-12 | 2008-06-19 | Smithkline Beecham Corporation | Novel combinations |
WO2008074078A1 (en) * | 2006-12-19 | 2008-06-26 | University Of Wollongong | Selectively deliverable isatin-based cytotoxic agents |
US20110129550A1 (en) | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
UY30915A1 (es) | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
EP2211855A4 (en) * | 2007-10-09 | 2011-12-07 | Univ Pennsylvania | THROMBOPOIETIN RECEPTOR AGONIST (TPORA) DESTROYING THE CELLS OF ACUTE HUMAN MYELOID LEUKEMIA |
WO2009140464A1 (en) * | 2008-05-16 | 2009-11-19 | Ligand Pharmaceuticals, Inc. | Methods of administration of thrombopoietin mimetic compounds |
US8476249B2 (en) | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
US8680150B2 (en) * | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
US9492430B2 (en) * | 2011-11-14 | 2016-11-15 | Ligand Pharmaceuticals, Incorporated | Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
WO2014150252A1 (en) * | 2013-03-15 | 2014-09-25 | Ligand Pharmaceuticals Incorporated | Methods of treatment associated with the granulocyte colony-stimulating factor receptor |
US9493413B2 (en) | 2013-11-27 | 2016-11-15 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
DK3373937T3 (da) | 2015-11-09 | 2022-03-14 | Scherer Technologies Llc R P | Anti-cd22-antistof-maytansin-konjugater og fremgangsmåder til anvendelse deraf |
CN106632407A (zh) * | 2016-09-30 | 2017-05-10 | 陕西科技大学 | 一种具抗肿瘤活性的不对称双7‑n杂靛红席夫碱类化合物的合成方法 |
AU2020257272A1 (en) * | 2019-04-17 | 2021-11-11 | Colorado Research Partners LLC | Novel compounds and methods of use treating fructose-related disorders or diseases |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE653800A (es) | ||||
DE193633C (es) | ||||
US3148192A (en) | 1961-06-27 | 1964-09-08 | Roussel Uclaf | Halogenated 20alpha-yohimbane compounds |
DE450819C (de) | 1924-12-24 | 1927-10-20 | Chemische Ind Ges | Verfahren zur Herstellung von chromhaltigen Azofarbstoffen |
GB252957A (en) | 1926-02-19 | 1926-06-10 | Chem Fab Vormals Sandoz | Manufacture of diazotizable azo-dyestuffs and intermediate products therefor |
GB898706A (en) | 1957-09-20 | 1962-06-14 | Polaroid Corp | Azo dyes derived from dihydroxyphenyl ketones and their use in photography |
NL255336A (es) | 1959-08-29 | |||
GB1080864A (en) | 1963-02-26 | 1967-08-23 | Ici Ltd | Five membered heterocyclic systems and their use as fungicides |
GB1269781A (en) | 1968-11-12 | 1972-04-06 | Ici Ltd | Alkanolamine derivatives |
US3966900A (en) | 1969-03-12 | 1976-06-29 | Airwick Industries, Inc. | Evaporator system comprising a stabilized pesticidal phosphoric acid ester and method for stabilizing such ester enclosed in an evaporator |
US3754857A (en) | 1969-08-27 | 1973-08-28 | American Cyanamid Co | Polyethylene terephthalate,nylon and organic esters of cellulose dyedwith 5-(2-nitro-pranisylazo) barbituric acid |
EP0034725B1 (de) | 1980-02-18 | 1984-07-25 | BASF Aktiengesellschaft | Imidazolylmethylgruppen enthaltende Farbstoffe und deren Verwendung |
US4322533A (en) | 1980-03-17 | 1982-03-30 | Lesher George Y | 1H-Indole-2,3-dione derivatives |
DE3329340A1 (de) | 1983-08-13 | 1985-03-07 | Basf Ag, 6700 Ludwigshafen | Verlackungsmittel enthaltende farbstoffzubereitungen basischer farbstoffe |
DE3434379A1 (de) | 1984-09-19 | 1986-03-20 | Basf Farben + Fasern Ag, 2000 Hamburg | Pigmentzubereitungen |
GB8431426D0 (en) * | 1984-12-13 | 1985-01-23 | Glaxo Group Ltd | Chemical compounds |
DE3743235A1 (de) | 1987-12-19 | 1989-06-29 | Bayer Ag | Basische farbstoffe |
DE3810958A1 (de) | 1988-03-31 | 1989-10-12 | Basf Ag | Tinten fuer ink-jet-aufzeichnungsverfahren |
GB8816944D0 (en) | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
JP2683097B2 (ja) | 1989-04-28 | 1997-11-26 | キヤノン株式会社 | 電子写真感光体 |
US5164404A (en) | 1991-03-15 | 1992-11-17 | Neurosearch A/S | Hydrazone derivatives and their use |
JP2709750B2 (ja) | 1991-03-27 | 1998-02-04 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
US5298658A (en) | 1991-12-20 | 1994-03-29 | E. I. Du Pont De Nemours And Company | Photographic elements with reduced print-through |
DE4335623A1 (de) | 1993-10-19 | 1995-04-20 | Henkel Kgaa | Indolinon-Derivate zum Färben keratinhaltiger Fasern |
US5482546A (en) | 1994-03-30 | 1996-01-09 | Canon Kabushiki Kaisha | Dye, ink containing the same, and ink-jet recording method and instrument using the ink |
DE69503849T2 (de) | 1994-03-31 | 1999-04-01 | Amgen Inc., Thousand Oaks, Calif. | Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten |
US6184363B1 (en) | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
US6075044A (en) | 1997-07-21 | 2000-06-13 | The Regents Of The University Of California | Heterocyclic derivatives as inhibitors of purine salvage phosphoribosyltransferases |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6649631B1 (en) | 1997-10-23 | 2003-11-18 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating bone deficit conditions |
GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
JP2000206645A (ja) | 1999-01-18 | 2000-07-28 | Fuji Photo Film Co Ltd | 画像形成材料および画像形成方法 |
GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
CN1376150A (zh) | 1999-07-26 | 2002-10-23 | 盐野义制药株式会社 | 具有血栓形成素受体拮抗作用的药物组合物 |
EP1213965B1 (en) | 1999-09-10 | 2006-01-18 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
JP2003509462A (ja) | 1999-09-24 | 2003-03-11 | スミスクライン・ビーチャム・コーポレイション | トロンボポイエチン模倣物 |
US6720345B1 (en) | 1999-11-05 | 2004-04-13 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
JP2001152055A (ja) | 1999-11-26 | 2001-06-05 | Fuji Photo Film Co Ltd | インクジェット記録用インクおよびそれを用いた画像記録方法 |
CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
JP4359382B2 (ja) | 2000-07-11 | 2009-11-04 | 富士フイルム株式会社 | 新規なヒドラゾン色素 |
JP2004508366A (ja) | 2000-09-01 | 2004-03-18 | グラクソ グループ リミテッド | オキシインドール誘導体 |
JP2004517049A (ja) | 2000-09-01 | 2004-06-10 | グラクソ グループ リミテッド | チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 |
US6642265B1 (en) | 2000-09-08 | 2003-11-04 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
JP2002129072A (ja) | 2000-10-20 | 2002-05-09 | Fuji Photo Film Co Ltd | インクジェット記録用インク及びそれを用いた画像記録方法 |
JP2002129073A (ja) | 2000-10-20 | 2002-05-09 | Fuji Photo Film Co Ltd | 油性インク組成物 |
EP1349613A4 (en) | 2000-12-19 | 2005-09-21 | Smithkline Beecham Corp | THROMBOPOIETINMIMETIKA |
CA2432800A1 (en) | 2000-12-21 | 2002-07-25 | Smithkline Beecham Corporation | Regulated activation of cell-membrane receptors by metal-chelating agonists |
EP1361220A4 (en) | 2001-01-26 | 2005-09-07 | Shionogi & Co | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM |
US6875786B2 (en) | 2001-03-01 | 2005-04-05 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
JP4343534B2 (ja) | 2001-03-02 | 2009-10-14 | ゲーペーツェー バイオテック アクチェンゲゼルシャフト | 3ハイブリッド・アッセイ・システム |
GB0106343D0 (en) | 2001-03-14 | 2001-05-02 | Avecia Ltd | Compounds compositions and processes |
IL160010A0 (en) | 2001-07-23 | 2004-06-20 | Univ Ramot | Methods and compositions for treating fungal infections |
WO2003011287A1 (en) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
JP2003128946A (ja) | 2001-10-26 | 2003-05-08 | Fuji Photo Film Co Ltd | 新規なアゾ色素、及び該アゾ色素の互変異性体 |
GB0126036D0 (en) | 2001-10-30 | 2001-12-19 | Amedis Pharm Ltd | Silicon compounds |
KR101010905B1 (ko) | 2002-01-18 | 2011-01-25 | 아스텔라스세이야쿠 가부시키가이샤 | 2-아실아미노티아졸 유도체 또는 그 염 |
US20050049267A1 (en) | 2002-03-01 | 2005-03-03 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
AU2003230765A1 (en) | 2002-03-29 | 2003-10-13 | Bayhill Therapeutics, Inc. | Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
US20030229453A1 (en) | 2002-04-09 | 2003-12-11 | Antonysamy Stephen Suresh | Crystals and structures of PAK4KD kinase PAK4KD |
JP2003313450A (ja) | 2002-04-22 | 2003-11-06 | Fuji Photo Film Co Ltd | アゾ色素及びその互変異性体 |
JP2003335972A (ja) | 2002-05-21 | 2003-11-28 | Fuji Photo Film Co Ltd | アゾ化合物及びその製造方法 |
TWI280128B (en) | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
EP1556059A4 (en) | 2002-06-06 | 2010-06-30 | Smithkline Beecham | MIMETICS OF THROMBOPOIETINE |
TWI324593B (en) | 2002-10-09 | 2010-05-11 | Nissan Chemical Ind Ltd | Pyrazolone compounds and thrombopoietin receptor activator |
JP2004143118A (ja) | 2002-10-28 | 2004-05-20 | Fuji Photo Film Co Ltd | アゾ化合物及びその互変異性体、並びに、その製造方法 |
US20060084682A1 (en) | 2002-12-13 | 2006-04-20 | Heerding Dirk A | Thrombopoietin mimetics |
US20040253178A1 (en) | 2002-12-20 | 2004-12-16 | Shane Atwell | Crystals and structures of spleen tyrosine kinase SYKKD |
WO2004096154A2 (en) | 2003-04-29 | 2004-11-11 | Smithkline Beecham Corporation | Methods for treating degenerative diseases/injuries |
WO2004105587A2 (en) * | 2003-05-28 | 2004-12-09 | Medcool, Inc. | Methods and apparatus for thermally activating a console of a thermal delivery system |
UA82695C2 (uk) | 2003-06-06 | 2008-05-12 | Нисан Кемикал Индастриз, Лтд. | Гетероароматичні сполуки як активатори рецептора тромбопоетину |
CA2563316A1 (en) | 2004-04-06 | 2005-10-20 | Semafore Pharmaceuticals, Inc. | Pten inhibitors |
BRPI0511057A (pt) | 2004-05-12 | 2007-11-27 | Bayer Cropscience Gmbh | regulação de crescimento da planta |
WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
SE0401790D0 (sv) | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
KR100958337B1 (ko) | 2004-10-25 | 2010-05-17 | 리간드 파마슈티칼스 인코포레이티드 | 트롬보포이에틴 활성 조절 화합물 및 방법 |
GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
US7563781B2 (en) | 2005-01-14 | 2009-07-21 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives |
WO2007062078A2 (en) | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
US20070162433A1 (en) | 2006-01-11 | 2007-07-12 | Peters James D | System and method for a secure process to perform distributed transactions |
-
2005
- 2005-10-21 KR KR1020077011701A patent/KR100958337B1/ko active IP Right Grant
- 2005-10-21 JP JP2007538100A patent/JP4728340B2/ja active Active
- 2005-10-21 MX MX2007004765A patent/MX2007004765A/es active IP Right Grant
- 2005-10-21 US US11/256,572 patent/US7314887B2/en active Active
- 2005-10-21 AU AU2005299720A patent/AU2005299720B2/en not_active Ceased
- 2005-10-21 BR BRPI0516883-0A patent/BRPI0516883A/pt not_active Application Discontinuation
- 2005-10-21 EP EP05813834A patent/EP1805155B1/en active Active
- 2005-10-21 WO PCT/US2005/038055 patent/WO2006047344A1/en active Application Filing
- 2005-10-21 AT AT05813834T patent/ATE486859T1/de not_active IP Right Cessation
- 2005-10-21 CA CA002583764A patent/CA2583764C/en not_active Expired - Fee Related
- 2005-10-21 DE DE602005024599T patent/DE602005024599D1/de active Active
- 2005-10-21 NZ NZ554662A patent/NZ554662A/en not_active IP Right Cessation
- 2005-10-25 AR ARP050104466A patent/AR051940A1/es not_active Application Discontinuation
-
2007
- 2007-04-23 IL IL182763A patent/IL182763A/en not_active IP Right Cessation
- 2007-04-27 NO NO20072199A patent/NO20072199L/no not_active Application Discontinuation
- 2007-11-08 US US11/937,392 patent/US7691895B2/en not_active Expired - Fee Related
- 2007-12-21 US US11/963,115 patent/US20080103190A1/en not_active Abandoned
-
2008
- 2008-05-19 IL IL191542A patent/IL191542A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2005299720A1 (en) | 2006-05-04 |
KR20070084506A (ko) | 2007-08-24 |
US7691895B2 (en) | 2010-04-06 |
AU2005299720B2 (en) | 2010-02-04 |
US20060116417A1 (en) | 2006-06-01 |
NO20072199L (no) | 2007-06-05 |
NZ554662A (en) | 2008-11-28 |
US20080103190A1 (en) | 2008-05-01 |
BRPI0516883A (pt) | 2008-09-23 |
EP1805155B1 (en) | 2010-11-03 |
WO2006047344A1 (en) | 2006-05-04 |
KR100958337B1 (ko) | 2010-05-17 |
US7314887B2 (en) | 2008-01-01 |
IL191542A0 (en) | 2008-11-03 |
JP4728340B2 (ja) | 2011-07-20 |
MX2007004765A (es) | 2007-07-09 |
EP1805155A1 (en) | 2007-07-11 |
IL182763A (en) | 2010-12-30 |
DE602005024599D1 (de) | 2010-12-16 |
JP2008517932A (ja) | 2008-05-29 |
CA2583764A1 (en) | 2006-05-04 |
IL191542A (en) | 2013-08-29 |
ATE486859T1 (de) | 2010-11-15 |
US20080146594A1 (en) | 2008-06-19 |
IL182763A0 (en) | 2007-07-24 |
CA2583764C (en) | 2009-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051940A1 (es) | Compuestos y metodos para modular la actividad de la trombopoyetina | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
AR086977A1 (es) | Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen | |
AR081626A1 (es) | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos | |
PE20090159A1 (es) | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs | |
AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
AR086972A1 (es) | Procesos para preparar compuestos heterociclicos, que incluyen trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma | |
AR045510A1 (es) | Derivados de 1,3 diazoles | |
AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
NZ610312A (en) | 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors | |
AR066348A1 (es) | Inhibidores de las iap | |
RU2008108898A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
AR058402A1 (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas.composiciones farmaceuticas. | |
PE20091444A1 (es) | Derivados de isoxazolo-pirazina | |
AR068466A1 (es) | Cianoisoquinolina | |
AR054272A1 (es) | Derivados de 3- aminopirrilidinas tri, tetra - sustituidos | |
AR068888A1 (es) | Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp. | |
PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
CO6351734A2 (es) | Compuestos de amida utiles en terapia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal | ||
FC | Refusal | ||
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |